Avid Bioservices Inc (CDMO)

[sunstar]

“Planned studies include bavituximab in combination with pembrolizumab in hepatocellular carcinoma, and durvalumab in NSCLC.”

“7.0 Drug Supply”

“Bavituximab will be supplied for all approved and funded studies by Grantor.
If bavituximab is studied in combination with an investigational agent from another pharmaceutical company, or an agent is used outside of its indication, the investigator must provide documentation of that company’s commitment to provide drug for the investigation as well as the agreement of that company to allow presentation and publication of results, and allow cross-filing or filing of a new IND. If pharmacokinetic studies of investigational agents other than bavituximab are planned, the investigator must provide documentation of that company’s commitment to or alternative mechanism for performing PK studies for that agent. This documentation must be provided to NCCN along with the proposal.”

“Diagnostic assays and other correlative study assays will be supplied for all approved and funded studies by Peregrine Pharmaceuticals.”

http://cancer.ucsf.edu/intranet/sm_files/NCCN%20Bavituximab%20RFP.pdf

sunstar